Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells.

Autor: Lipreri da Silva JC; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Lima K; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Ede B; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Lazarini M; Department of Clinical and Experimental Oncology, Federal University of São Paulo, São Paulo, Brazil., Vicari HP; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Nogueira FL; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Clayton NS; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Pinnell K; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Silva WFD; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Velloso EDRP; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Bendit I; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Costa-Lotufo LV; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Rego EM; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Ridley AJ; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Machado-Neto JA; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: jamachadoneto@usp.br.

Publikováno v: European journal of pharmacology [Eur J Pharmacol] 2024 Nov 29; Vol. 987, pp. 177161. Date of Electronic Publication: 2024 Nov 29.